DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zontivity (Vorapaxar Sulfate) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Effects of Other Drugs on ZONTIVITY

Vorapaxar is eliminated primarily by metabolism, with contributions from CYP3A4 and CYP2J2.

Strong CYP3A Inhibitors

Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions and Clinical Pharmacology].

Strong CYP3A Inducers

Avoid concomitant use of ZONTIVITY with strong inducers of CYP3A (e.g., rifampin, carbamazepine, St. John's Wort and phenytoin) [see Warnings and Precautions and Clinical Pharmacology].

OVERDOSAGE

There is no known treatment to reverse the antiplatelet effect of ZONTIVITY, and neither dialysis nor platelet transfusion can be expected to be beneficial if bleeding occurs after overdose. Inhibition of platelet aggregation can be expected for weeks after discontinuation of normal dosing [see Clinical Pharmacology]. There is no standard test available to assess the risk of bleeding in an overdose situation.

CONTRAINDICATIONS

History of Stroke, Transient Ischemic Attack (TIA), or Intracranial Hemorrhage (ICH)

ZONTIVITY is contraindicated in patients with a history of stroke, TIA, or ICH because of an increased risk of ICH in this population [see Adverse Reactions (6) ].

Discontinue ZONTIVITY in patients who experience a stroke, TIA, or ICH [see Adverse Reactions and Clinical Studies].

Active Pathologic Bleeding

ZONTIVITY is contraindicated in patients with active pathological bleeding such as ICH or peptic ulcer [see Warnings and Precautions and Adverse Reactions].

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017